First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer modelsSeyed Pairawan, Funda Meric‐Bernstam|Breast Cancer Research|2021Cited by 67
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsSeyed Pairawan, Funda Meric‐Bernstam|Scientific Reports|2022Cited by 9